AVIPERO Announces JB1a Reverses Tissue Damage and Induces Tissue Repair in Emphysema
AVIPERO (Registered in Scotland SC353945) announced today the results of its first R&D therapeutic platform in non-stem cell tissue repair and regeneration. The principal candidate, JB1a, is an antibody targeting the cell surface adhesion receptor beta1 integrin. The preclinical study, funded... - November 18, 2011
Press Releases 1 - 1 of 1